Table 2. Analyses of prognostic factors for progression-free survival in patients with cervical cancer.
| Variable | Test for PFS | HR | 95% CI | p-value |
|---|---|---|---|---|
| Age (yr) | 1.000 | 0.946-1.057 | 0.999 | |
| FIGO stage | II vs. I | 3.746 | 1.290-10.881 | 0.015 |
| Tumor size | 1.177 | 0.924-1.500 | 0.188 | |
| LN metastasis | Present vs. absent | 1.716 | 0.536-5.497 | 0.363 |
| PM invasion | Present vs. absent | 1.899 | 0.594-6.066 | 0.279 |
| SUVtumor | 1.040 | 1.008-1.072 | 0.015 | |
| MTVtumor | 1.020 | 1.008-1.032 | 0.001 | |
| TLGtumor | 1.001 | 1.001-1.002 | <0.001 | |
| SUVLN | 1.105 | 1.031-1.184 | 0.004 | |
| IFH | 34.586 | 2.853-419.310 | 0.005 |
FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; IFH, intratumoral [18F]fluorodeoxyglucose (FDG) uptake heterogeneity; LN, lymph node; MTV, metabolic tumor value; PFS, progression-free survival; PM, parametrium; SUV, standardized uptake value; TLG, total lesion glycolysis.